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Abstract African nonhuman primates that are natural hosts
of simian immunodeficiency virus (SIV) are generally
spared from disease progression. Pathogenic and nonpatho-
genic SIV infections share some major features: high viral
replication, massive acute depletion of mucosal CD4
+ T
cells, and partial control of the virus by both adaptive and
innate immune responses. A key distinction of natural SIV
infections is rapid and active control of immune activation
and apoptosis of T cells that contributes to the integrity of
mucosal barrier and lack of microbial translocation. This
allows partial recovery of CD4
+ T cells and preservation of
the function of other immune cell subsets. A better
understanding of the mechanisms underlying the lack of
disease in natural hosts for SIV infection will likely provide
important clues as to the therapy of HIV-1 infection.
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replication.CD4+Tcells.Immuneactivation.Innate
immunity.Africangreenmonkey.Sootymangabey
Introduction
Without treatment, HIV-1 infection progresses to AIDS in 7
to 10 years. The survival of HIV-infected patients consid-
erably increased with the use of highly active antiretroviral
therapy (HAART). Nowadays, a newly HIV-infected 20-
year-old who receives appropriate treatment early in the
infection has a life expectancy of at least 69 years.
Although these results are encouraging and unprecedented,
the adverse effects, prohibitive costs, and the issues of viral
resistance to antiretroviral drugs are still limiting factors
of HAART. Complementary approaches to antiretroviral
therapy, aimed at upholding immune system function
through immunotherapies, are likely needed to transform
HIV infection into a chronic, life-lasting, treatable condition.
This new focus on the development of immunotherapies
as an approach to prevent HIV disease progression is
supported by numerous lines of evidence that have
accumulated during recent years and generated a new
paradigm in which excessive immune activation and T-cell
proliferation are major determinants of progression to AIDS
[1, 2]. Particularly, this new concept is fueled by data from
the study of persistent nonprogressive simian immunodefi-
ciency virus (SIV) infection in natural African nonhuman
primate (NHP) hosts [2].
In this review, we address the major aspects of SIV
pathogenesis in natural hosts, with emphasis on the
mechanisms of the lack of disease progression.
Simian Immunodeficiency Viruses
More than 40 SIVs naturally infect wild African NHPs,
with high prevalence [3]. In spite of being designated SIV,
by analogy with HIV, these viruses generally do not induce
immune suppression in their hosts [2]. This fundamental
difference is equally fascinating and intriguing. Obviously,
there is an important question raised by the lack of disease
progression of SIV infection in natural hosts: are these
highly divergent, apparently harmless viruses that infect
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Rapidly accumulating data on the pathogenesis of SIV
infection in natural hosts and in new hosts upon cross-
species transmission indicate that these “exotic” models
may actually hold clues regarding the immune correlates of
the control of SIV/HIV disease progression [2].
First, the viruses infecting African NHPs retained their
pathogenic potential. This is illustrated by their ability to
induce immunosuppression and disease progression in new
hosts upon cross-species transmission [3]. HIV-1 and HIV-
2, the two viruses causing AIDS in humans, resulted from
cross-species transmissions from chimpanzees/gorillas and
sooty mangabeys (SMs), respectively [3]. Also, accidental
transmission of SIVsmm, which naturally infects SMs, to
different species of Asian macaques resulted in progressive
infections in the new hosts [4]. Moreover, rare AIDS cases
were reported in several African NHP species infected with
their species-specific or cross-species transmitted SIVs [5].
These cases were described during long-term follow-up
after extensive incubation periods in captive animals that
outlived the normal species lifespan in the wild. They
recapitulate all virologic, immunologic, and clinical con-
ditions that usually define AIDS in humans [5].
Second, the benign coexistence of SIVs and their
African NHP hosts resulted from their interactions over
millennia [3], and a long-term adaptation of the primate
hosts to prevent the deleterious consequences of lentiviral
infection. Although the mechanisms through which the
nonpathogenicity was achieved are still under debate, this
adaptation resulted in a pattern of chronic, persistent, life-
lasting infection with an incubation period that normally
exceeds the lifespan of the species [5]. Because this is the
target of current therapeutic approaches in HIV infection,
the study of SIV infection in natural hosts can provide
invaluable clues with regard to which aspects of HIV
pathogenesis have to be manipulated to successfully control
disease progression.
Particularities of the Immune System of Natural Hosts
of SIV
The long-term virus–host coevolution left immunologic
imprints in the natural hosts of SIVs.
The CCR5 expression (protein and mRNA) by CD4
+ T
cells from periphery, lymphoid, and mucosal tissues was
found to be significantly lower in uninfected natural hosts,
such as African green monkeys (AGMs), mandrills, SMs,
solatus monkeys, and patas monkeys, compared with
progressive hosts, such as rhesus macaques (RMs), pig-
tailed macaques, and humans [6]. Interestingly, the CD8
+ T
cells isolated from natural hosts express normal levels of
CCR5, thus indicating that the finding is not a technical
artifact [6]. Furthermore, CCR5 expression on the CD4
+ T
cells was particularly low in newborn AGMs and mandrills,
compared with adults of the same species. Differently from
RMs, in which CCR5 levels rapidly increase in infants of
6 months of age, reaching levels similar to those expressed
by adults, such increases could not be observed in infant
and juvenile African monkeys less than 3 years old [7•].
The red-capped mangabey (RCM) is an extreme exam-
ple of a natural host that totally lacks CCR5 expression, as
a result of a high prevalence (83%) in this species of a
delta-24a deletion [8] that prevents CCR5 gene transcrip-
tion. This situation recalls the minority of humans who
have a delta-32 deletion in the CCR5 gene structure that
renders them resistant to HIV infection or disease progres-
sion [9]. Differently from HIV-1, which mainly uses CCR5
as a coreceptor, SIVrcm (the virus that naturally infects
RCMs without clinical consequences) adapted to use a
CCR2 or CCR4 coreceptor to ensure persistence in the
RCM host [10].
These observations led to our original hypothesis that the
changes in CCR5 expression in natural hosts reflect the
coevolution of the viruses with their hosts [6]. This
hypothesis is supported by the observation that, in baboons,
CCR5 expression on CD4
+ T cells is similar to that
observed in humans and macaques [6]. Baboons are not
natural hosts for SIV and progress to AIDS upon SIV/HIV-
2 infections [5].
In chimpanzees, CCR5 expression on CD4
+ T cells is at
intermediate levels between humans and natural NHP hosts
[6], in line with molecular analyses that showed that
chimpanzees acquired SIVcpz through cross-species trans-
missions from other monkey species, thus emerging more
recently than the SIVs infecting African monkey species
[3]. Moreover, SIVcpz is pathogenic in chimpanzees [11•].
To conclude, CCR5 expression by CD4
+ T cells
correlates with the ability of NHP species to develop or
resist disease progression when infected with HIV/SIV.
The second difference in the immune system of the
natural versus progressive hosts is that some African NHP
species, such as AGMs, patas, and solatus monkeys, have
low numbers of CD4
+ T cells [12]. These low levels of
CD4
+ T cells appear to be characteristic only for African
guenons (tribe Cercopithecini), as SMs and mandrills (tribe
Papionini) were reported to have higher CD4
+ T cell
counts, similar to RMs, which belong to the same tribe.
Over the years, it was also reported that a large
proportion of the CD3
+ T cells do not express either CD4
or CD8, in natural hosts [13, 14•, 15, 16]. Recently, these
double-negative cells where shown to arise through CD4
downregulation, as the cells enter the memory pool. This
downregulation is independent of SIV infection. The
CD4
neg memory T cells maintain functions attributed to
CD4
+ T cells, including production of interleukin (IL)-2
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and expression of CD40 ligand and of forkhead box P3 [13,
14•]. In contrast with the double-negative T cells observed
in HIV-infected patients (which also occur through down-
regulation of CD4 [17]), the double-negative cells from
AGMs are not SIV infected [14•]. Preservation of a cell
subset that maintains CD4
+ T-cell function while being
resistant to SIV infection in vivo may be responsible for the
lack of disease progression in natural hosts. The precise
impact of the double-negative T-cell population for SIV
transmission and pathogenesis remains to be determined.
Recent studies reported differences in the functionality
of dendritic cells between pathogenic and nonpathogenic
hosts. Thus, two studies reported that AGM and SM
plasmacytoid dendritic cells (pDCs) produce markedly less
interferon (IFN)-α in response to SIV and other Toll-like
receptor (TLR) 7 and 9 ligands ex vivo [18, 19]. Such an
observation may suggest that, in contrast with progressive
hosts in which chronic stimulation of pDCs by SIV/HIV
may drive the unrelenting immune system activation and
dysfunction underlying AIDS progression, such a vicious
cycle of continuous virus replication and immunopathology
is absent in natural hosts.
These particularities of the immune system of natural
hosts may have significant impact on the pathogenicity of
SIV infection in these species (Table 1). One can imagine
that the low levels of target cells (cells expressing CD4 and
CCR5) may result in lower rates of SIV transmission or
lower viral replication in natural hosts than in new hosts.
Also, the low expression of CCR5 on the CD4
+ T cells and
a reduced capacity of the innate immunity to activate the
adaptive immune system may result in lower levels of
immune activation in the natural host than in progressive
infections.
SIV Mucosal Transmission in Natural Hosts
The observation that natural hosts of SIV have low levels of
CCR5
+CD4
+ T cells at mucosal sites raised the question of
whether the virus can be transmitted through mucosal
routes in these species. This hypothesis was also suggested
by the observation that in offspring and juvenile monkeys,
which have even lower levels of CCR5
+CD4
+ cells at
mucosal sites, breastfeeding transmission is significantly
lower than in pathogenic infection [7•]. However, the
prevalence of SIV infection in wild populations of natural
hosts significantly increases in adult animals, suggesting
sexual transmission [3].
Experiments in mandrills failed to demonstrate any
breastfeeding transmission of SIVmnd-1, even when man-
drill dames were infected on the day of the delivery [7•]. In
spite of very high viral load (VL) levels during the acute
and chronic infection of the dames, and of high levels of
replicating virus in milk during acute infection, no case of
SIVmnd-1 transmission to offspring was observed during
the lactation period. The design of this study, with dames
being infected after delivery, precluded protection of the
offspring through passively transmitted maternal antibodies.
The lack of breastfeeding transmission in natural hosts was
therefore correlated with the low CCR5 expression at
mucosal sites [7•].
In a recent experiment, we assessed for the first time the
efficacy of mucosal SIV transmission in a natural host by
performing a dose-escalation study, in which AGMs and
pigtailed macaques were intrarectally exposed to SIVagm
(Pandrea, Unpublished data). This experiment demonstrated
that natural hosts of SIVs can be infected by mucosal
transmission, but at higher doses compared with pigtailed
macaques. The efficacy of transmission was lower in
juvenile animals than in adult AGMs, also suggesting that
transmissibility depends on the availability of target cells at
the mucosal sites. All these findings point toward a strong
correlation between the levels of CCR5 expression on the
CD4
+ T cells and the rates of SIV transmission. Our studies
also suggest that blockage of CCR5 may be an efficient
treatment in preventing breastfeeding transmission, in
addition to vaginal or rectal transmission.
SIV Replication in Natural Hosts
Despite the low levels of target cells, SIV replicates to high
levels in natural hosts [20]. During acute infection, VLs are
in the same range as those reported for pathogenic HIV/SIV
infections [21]. During chronic infection of natural hosts,
the levels of viral replication are slightly higher [20] than
those observed in HIV-1–infected patients [22]. In contrast
with pathogenic infections, the levels of viral replication are
remarkably stable for decades during chronic infection of
natural hosts [23, 24].
There are several observations that have to be stressed
with regard to SIV replication in the natural host. First,
similar to humans and macaques, plasma viremia during
chronic infection is predictive of disease progression. The
levels of chronic viral replication were significantly higher
in African monkeys that progressed to AIDS than in those
that resisted progression [5]. Note, however, that even these
progressor monkeys showed a remarkable resilience to high
levels of viral replication, which were maintained for
decades prior to disease progression [5]. Second, SIV VLs
in natural hosts appear to be dependent on the availability
of CD4
+ T cells. Multiple lines of evidence support this
conclusion: 1) In AGMs, a lower baseline level of CD4
+ T
cells associates steady-state levels of viral replication that
are 1 log lower than in SMs and mandrills [20]; 2) In SMs
30 Curr HIV/AIDS Rep (2010) 7:28–36and AGMs with severe CD4
+ T-cell depletion after SIV
infection, VLs decreased significantly [25]; 3) Experimen-
tal induction of immune activation in chronically infected
AGMs resulted in a dramatic increase in the number of
CD4
+ T cells and VLs [26•]; and 4) As expected from
previous studies in AGMs, experimental CD4
+ T-cell
depletion in SMs resulted in a significant decrease of VLs
[27].
The low CCR5 expression observed in uninfected
African NHPs does not appear to have a major impact on
virus replication in the natural host. This paradox may be
explained through several hypotheses. First, CCR5 expres-
sion may increase in response to SIV infection. The CCR5
+
CD4
+ T cells are targeted and depleted by the SIV.
Therefore, SIV-associated changes in the CD4
+ CCR5
+
T-cell pool may reflect the opposing forces of both SIV
replication (which reduces this cellular pool) and immune
activation (which increases it). In AGMs, CCR5 expression
by CD4
+ T cells (both protein and mRNA levels) increases
during acute SIVagm infection, as well as at certain time
points during chronic infection. These increases in the
CCR5 expression on the CD4
+ T cells may be sufficient to
expand the pool of SIV target cells and maintain the high
VLs. Being only transient, these increases in CCR5
expression are not harmful to the hosts by not triggering
excessive immune activation. Second, natural hosts may
keep the CCR5 expression under control through an active
mechanism, which remains to be determined. Finally, the
lack of correlation between coreceptor expression and the
levels of viral replication may be due to SIVs having other
target cells in natural hosts.
Indeed, the paradox of SIV infection in natural hosts
defined by association of a paucity of CD4
+ CCR5
+ target
cells with high VLs also raised the question of whether in
natural hosts SIVs could target cells other than CD4
+ T
lymphocytes. This hypothesis is also prompted by the
observation that peripheral CD4
+ T cells are well preserved
in natural hosts during chronic infection, almost at
preinfection levels. Such alternative potential target cell
candidates may be either the macrophages or CD4
+ T-cell
subsets that do not express CCR5.
In some AGMs, the levels of SIVagm in the brain are as
high as in humans with HIV-dementia [28], and the SIVagm
strains isolated from the brain of infected AGMs are
macrophage tropic. In the same animals, the SIVagm strains
isolated from the lymph nodes were more restricted to
growth in human T-cell lines [28]. These results suggest
compartmentalization in the central nervous system without
Table 1 Comparison between pathogenic and nonpathogenic SIV infection
Parameter Persistent progressive infection Persistent nonprogressive infection
Acute viral replication High High
Chronic viral replication High and short length set point followed
loss of control
High but indefinitely maintained set point
Mutation rates High High
Tissue reservoirs Lymph nodes, intestine, brain Lymph nodes, intestine, brain
Target cells Mainly lymphocytes, secondary macrophages Mainly lymphocytes, secondary macrophages
Peripheral CD4+ T cells Massive acute depletion; continuous loss
during chronic infection
Massive acute depletion; almost
complete recovery during chronic phase
Mucosal CD4+ T cells Massive acute depletion; continuous loss
during chronic infection
Massive acute depletion; partial recovery
during the chronic phase
Tregs Depleted during the chronic infection Preserved during the chronic infection
T helper 17 cells Depleted during the chronic infection Preserved during the chronic infection
T-cell proliferation Accelerated Normal
T-cell activation Increased Normal
Proinflammatory cytokines Increased Normal
Anti-inflammatory cytokines Delayed increase during acute infection Very early increase during acute infection
Apoptosis Increased Normal
Functionality of immune cells Impaired Normal
Cellular immune responses Moderate Moderate
Humoral immune responses Moderate Moderate
Intestinal barrier Damaged Maintained
Microbial translocation Increased Absent
CCR5 expression on CD4+ T cells High Very low
SIV simian immunodeficiency virus
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that the nonpathogenic nature of SIV infection in natural
hosts is not due to differences in the tissue and cell tropism
from those for HIV-1–infected patients or SIV-infected
macaques [28].
Similar to pathogenic infections, the bulk of viral
replication is supported in natural hosts by lymphocytes
rather than macrophages during both acute and chronic
infection:
1) A dramatic depletion of CD4
+ T cells occurs during
acute infection in natural hosts [29, 30]. At mucosal
sites, depletion is of the same magnitude as in
progressive infections [29, 30] and strongly suggests
that nonpathogenicity of SIV infection in natural hosts
is not due to preservation of mucosal CD4
+ T cells.
Both naïve and memory CD4
+ T-cell subsets are
massively depleted at mucosal sites during acute SIV
infection [29, 30]. T helper (Th) 17 cells were recently
reported to be preserved in natural hosts [13, 31]. With
the postacute partial control of viral replication and
immune activation, a partial restoration of mucosal
CD4
+ T cells occurs during chronic infection in natural
hosts [29, 30]. Altogether, these results demonstrate
that the magnitude of acute mucosal CD4
+ T-cell
depletion cannot predict progression to AIDS [29]
and that prolonged survival correlates with the levels of
CD4
+ T-cell recovery.
2) During the acute infection, in situ studies demonstrated
that SIVs mainly colocalize with T cells, colocalization
with macrophages being negligible.
3) Viral dynamics studies in natural hosts also showed
that viral replication occurs in short-lived cells that
have a shorter average lifespan than those reported for
HIV-infected humans and SIVmac-infected macaques
[32, 33].
On the other hand, SIVagm.sab and other viruses infecting
natural hosts were reported to be dual tropic in vitro and to
use both CCR5 and CXCR4 [34], being therefore conceiv-
able that the main target cells of these viruses are other CD4
+
T-cell subpopulations (ie, those expressing CXCR4). How-
ever, in vivo, SIVagm severely depletes the CD4
+ Tc e l l s
from the intestine (which more frequently express CCR5)
and not from the blood or lymph nodes (that have a higher
CXCR4 expression) in both nonprogressive (AGMs) [29]
and cross-species transmitted (RMs and pigtailed macaques)
infections [29]. This observation suggests that the virus is in
fact CCR5 tropic in vivo.
Altogether these data show that SIVs naturally infecting
African NHPs have the same biology and similar target
cells compared with the lentiviruses that infect humans or
macaques.
Immune Responses to SIV Infection in Natural Hosts
Studies suggested that SIV infection in natural hosts is
independent of immune responses. The main argument is
that, differently from elite controllers in which the lack of
disease progression is achieved through control of viral
replication [35], such control is not observed in natural
hosts [20]. Note, however, that the stability of VLs over
decades strongly supports an active (albeit partial) control
of viral replication in natural hosts.
Numerous studies determined that, in natural hosts, the
levels of anti-SIV binding and neutralizing antibodies are
either low or in the same range as those reported for HIV-1
infection [36]. Natural hosts usually lack anti-Gag anti-
bodies [36, 37]. The significance of this observation is still
debated, as the Gag antigens appear to be expressed, and
the Gag-specific T-cell responses are comparable to those
observed in pathogenic infections [37]. Neutralizing anti-
bodies of variable potency can be found in the majority of
SIV-seropositive AGMs [38, 39], and their detection is
dependent on the virus strain and the cells used for the
assay [38]. Most SIVsmm strains are resistant to neutrali-
zation [40]. These observations suggest that the low levels
of antibodies or the weak neutralization activity may be
responsible for the high viremia in these species [36].
Given the contradictory results of different studies, the
potential role of humoral immune responses for the control
of viral replication in natural hosts was assessed in AGMs
by ablating anti-SIV antibody production through a long-
term depletion of B cells. This study demonstrated that
humoral immune responses do not play a determinant
role in controlling viral replication in the natural host
[39]. This is also true for SIVsmm-infected macaques that
did not show significant changes in the levels of viral
replication or disease progression when depleted of B cells
and infected with a neutralization-sensitive SIVsmm strain
[40].
In contrast, cellular immune responses observed in
natural hosts seem to be involved in the control of viral
replication [37, 41, 42], with a direct correlation between
the levels of cellular immune responses and plasma VLs
being reported in SMs [43]. However, cellular immune
responses do not appear to be superior to those observed
during SIV infection of RMs [43].
Recently, several groups performed experimental in
vivo CD8 cell depletion studies in natural hosts and
reported that administration of anti-CD8 monoclonal
antibodies during both acute or chronic SIV infection
resulted in increases in the levels of virus replication in
both AGMs [44]a n dS M s[ 45]. During acute infection,
CD8 cell depletion did not result in a significant increase
of peak viremia, but in a plateau of high VLs after the
peak, which were controlled with the recovery of CD8
+ T
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vivo also resulted in an increase of viral replication in
natural hosts. Dual CD8
+ and CD20
+ cell depletion studies
also pointed to cellular immune responses as the main
factors involved in the control of viral replication in
natural hosts [44]. None of the in vivo immune cell
depletion studies reported any case of disease progression.
This is in line with the above observation that even in the
face of higher levels of viral replication, progression to
AIDS occurs only after very long incubation periods in
natural hosts [5].
Low Immune Activation is Pathognomonic for SIV
Infection in Natural Hosts
The assessment of the various contributing factors that
enable natural hosts of SIV to resist progression to AIDS
thus revealed that the lack of disease progression in natural
hosts is not due to 1) lower levels of SIV replication; 2)
preservation of peripheral or mucosal CD4
+ T cells during
acute infection; 3) replication in cell populations that are
different in natural versus pathogenic SIV infections; or 4)
exquisite SIV-specific cellular or humoral immune
responses.
The main difference identified between natural SIV
infections and pathogenic HIV/SIV infections relied on
the normal levels of immune activation and inflammation
observed in natural hosts. Generalized immune activation is
an important driver of viral replication disease progression
in pathogenic HIV/SIV infections [1]. Chronic SIV infec-
tion in natural hosts is associated with 1) low levels of
CD4
+ and CD8
+ T-cell activation and proliferation in the
periphery, as well as in lymphoid and mucosal tissues [29,
46]; 2) no significant increased levels of CD4
+ T-cell
apoptosis in vivo or in vitro [29, 47]; 3) absence of cell-
cycle dysregulation associated with pathogenic HIV/SIV
infections [48]; 4) no significant increase in the levels of
proinflammatory cytokines compared with uninfected
monkeys [26•, 39]; and 5) preserved function of the T-cell
regenerative compartment. During acute SIV infection of
natural hosts, the levels of T-cell activation and prolif-
eration, although transiently increased, are blunted
compared with those observed during pathogenic SIV-
m a ci n f e c t i o no fR M s ,w i t hal o w e rp e a ka n dam o r e
rapid and pronounced postpeak decline of immune
activation [29].
The low-level immune activation in natural hosts does
not appear to represent ignorance of, or tolerance to, SIV
antigens because SIV-specific T cells are present during
natural SIV infections and exert immune pressure on the
virus [41]. Moreover, an anti-inflammatory milieu was
reported to be rapidly established in AGMs after SIVagm
infection, characterized by an early increase in numbers of
Tregs, paralleled by an increase in transforming growth
factor-β and IL-10 levels in the plasma very early after
infection [49]. This anti-inflammatory milieu may actively
attenuate the immune activation during natural SIV infec-
tions. These observations conflict with a recent study in
SMs that reported that natural hosts intrinsically lack the
a b i l i t yt or e s p o n dt oT L Rs t i m u l a t i o ni nv i t r o[ 18].
However, in contrast with the in vitro data showing the
incapacity of pDCs to produce IFN-α, numerous recent in
vivo studies reported a transient increase of IFN-α
production during acute infection in AGMs and SMs and
an increased capacity of pDCs to produce IFN-α after
infection. These increases, however, are lower than those
observed in SIVmac-infected RMs and of very short
duration, with IFN-α production returning to baseline
levels by the time viral replication is controlled.
Fig. 1 Several mechanisms are
involved in the control of
immune activation in natural
hosts of simian immunodefi-
ciency viruses. In turn, normal
levels of immune activation may
result in prevention of disease
progression through several
pathways. pDCs plasmacytoid
dendritic cells; TLR Toll-like
receptor
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immune activation in the natural host (Fig. 1):
1) Viral factors, with a potential role for the nef gene
products of various SIVs (but not of HIVor SIVcpz) in
the protection of natural hosts against chronic immune
activation, CD4
+ T-cell depletion, and disease progres-
sion during natural SIV infection by downregulating
the expression of the CD3–TCR complex from the
surface of infected CD4
+ T cells [50].
2) The low CCR5 expression on the CD4
+ T cells may
contribute to reduced immune activation and inflam-
mation in the gut, by decreasing the homing of effector
memory cells to the intestine.
3) The anti-inflammatory milieu and reduced levels of
apoptosis of both lymphocytes and epithelial cells may
contribute to the maintenance of a healthy intestinal
barrier in natural hosts, thus preventing the release of
microbial TLRligands incirculation [29]. In both AGMs
and SMs there is no increase in microbial translocation
during SIV infection [29, 51], in great contrast with
progressive hosts, such as humans and RMs, in which
continuous leakage of microbial components through a
severely damaged intestinal mucosa was reported to be
responsible for maintaining high levels of immune
activation during lentiviral infection [51].
4) Preservation of Th-17 cells in natural hosts during SIV
infection may also play an important role in the
maintenance of the mucosal barrier, by preserving the
epithelial integrity providing protection against intesti-
nal flora [13, 31].
5) Preservation of T-regulatory cells in natural hosts may
reduce the levels of immune activation either by
production of anti-inflammatory cytokines, such as
IL-10, or by keeping T-cell proliferation at bay after
the initial CD4
+ T-cell loss. In pathogenic SIV/HIV
infections, increased turnover of T cells together with
increased cell death drive exhaustion of T-cell reserves
and progression to AIDS.
6) Finally, the innate immune system may also contribute
to the low levels of T-cell activation in the natural host,
by producing fewer proinflammatory cytokines, by
lower activation of the effector function of the adaptive
immune system, or by inducing Treg rather than Th1
differentiation.
Conclusions
African NHP species that are natural hosts of SIVs do not
progress to AIDS. Although SIV infection in natural hosts
shares numerous features with pathogenic infection, the
major difference relies in the effective control of immune
activation by natural hosts. Numerous mechanisms have
been proposed to be behind this fundamental difference
between natural and pathogenic SIV/HIV infections. Inten-
sive research is currently underway to establish which of
the pathways leading to the control of immune activation in
natural hosts could be exploited in order to control disease
progression in HIV-infected patients. It is highly likely that
several of these pathways are involved in controlling the
deleterious consequences of SIV infection in natural hosts.
Also, as these species learned how to cope with SIV
infection through a long-term coadaptation, it is equally
possible that different species followed different pathways.
To date, studies in natural hosts only focused on three
animal models, and numerous others are still unexplored.
Therefore, all these mechanisms should be investigated in
order to identify multiple strategies to keep HIV at bay and
control progression to AIDS. An approach that is too
simplistic will probably fail, as 20 years of study of natural
SIV infection has taught us that “for every complex
problem, there is an answer that is clear, simple—and
wrong” (H. L. Mencken) [52].
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